Efficacy of octreotide LAR (OCT) in patients (pts) with advanced neuroendocrine tumors (NET): A post hoc analysis of the placebo (PBO) arm of the phase III RADIANT-2 study with updated survival data.
Jonathan R. Strosberg
Consultant or Advisory Role - Novartis
Research Funding - Novartis
James C. Yao
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Emilio Bajetta
No relevant relationships to disclose
Mounir Aout
Employment or Leadership Position - Novartis
Bert Bakker
Employment or Leadership Position - Novartis
John D. Hainsworth
No relevant relationships to disclose
Philippe B. Ruszniewski
Employment or Leadership Position - Ipsen
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer
Research Funding - Ipsen; Novartis; Pfizer
Eric Van Cutsem
Research Funding - Novartis
Kjell E. Oberg
Consultant or Advisory Role - Camurus ; Ipsen; Novartis
Marianne E. Pavel
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer